A new semisynthetic derivative of the natural alkaloid, theobromine, has been designed as a lead antiangiogenic compound targeting the EGFR protein. The designed compound is an (m-tolyl)acetamide theo
Crystal Structure of EGFR T790M mutant in complex with naquotinib Descriptor: 6-ethyl-3-[[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]amino]-5-[(3R)-1-prop-2-enoylpyrrolidin-3-yl]oxy-pyrazin e-
Glioblastoma multiforme (GBM) is the most common and aggressive primary intracranial brain tumor in adults with a mean survival of 14 to 15 months. Aberrant activation of the epidermal growth factor r
EGFR L858R/V948R in complex with osimertinib and allosteric inhibitor JBJ-09-063 Descriptor: (2R)-2-(5-fluoro-2-hydroxyphenyl)-2-{6-[4-(1-methylpiperidin-4-yl)phenyl]-1-oxo-1,3-dihydro-2H-isoindol-2-y
Table S1, Top 15 selected fragments favoured in wild type EGFR inhibitors. Table S2, Description of some selected chemical descriptors. Table S3, The pair-wise correlation values of 7 docking energy-b